Sarepta Therapeutics' Q1 Performance Surpasses Expectations Amid Elevidys Challenges

Sarepta Therapeutics (NASDAQ:SRPT) reported strong first-quarter results in May 2026, with adjusted earnings and revenue exceeding expectations. However, the company faces challenges related to its flagship drug Elevidys due to safety concerns that impacted sales.

By Abdul Rahman Wed, May 20, 2026 at 3:36 PM GMT+3 2 min read · Yahoo Finance · May 20, 2026, 12:36 UTC

Tickers: $SRPT

Topics: drug launch FDA approval gene therapy revenue growth

Read the full article at Yahoo Finance

More World news

Linnworks Survey Reveals US E-commerce Businesses Limit AI Role to Operational Support Over Financial Control PR Newswire · November 12, 2026, 13:43 UTC
DocsInk Rebrands as TraceWell Health and Launches Integrated Care Platform PR Newswire · November 12, 2026, 13:44 UTC
Zoom Ventures Invests in Medaica to Advance AI-Powered Virtual Healthcare Seeking Alpha · November 12, 2026, 13:40 UTC
Rival Technologies Index Reveals Gen Z Financial Constraints Amidst Optimistic Outlook PR Newswire · November 12, 2026, 13:42 UTC
Canadian Cybersecurity Job Postings Rise While Entry-Level Opportunities Decline PR Newswire · November 12, 2026, 13:42 UTC
Klarna Appoints Robinhood's Chris Koegel as Chief Financial Officer Seeking Alpha · November 12, 2026, 13:35 UTC
Kyverna Therapeutics Reports Q3 GAAP EPS of -$0.68, Slightly Beating Estimates Seeking Alpha · November 12, 2026, 13:37 UTC
TelyRx Holdings Appoints Co-Founder Benjamin Atkins as Interim CEO Seeking Alpha · November 12, 2026, 13:38 UTC
Nvidia shares fall following analyst downgrades and reports of potential CEO leadership changes Seeking Alpha · November 12, 2026, 13:38 UTC
Technosylva Launches Technosylva Planning Application for Multi-Hazard Utility Risk Management PR Newswire · November 12, 2026, 13:38 UTC